Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

计划入组 15 人 · 首次发布于 2017 年 4 月 14 日

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

计划入组 1 人 · 首次发布于 2024 年 3 月 13 日

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

计划入组 11 人 · 首次发布于 2018 年 4 月 30 日

XIAP inhibitors(Genentech)

XIAP gene therapy (Neurologix)

XIAP antisense program (AVI BioPharma)

Rockwell Medical

United States

Ai-Media Technologies Ltd

United States

Shanghai Xiao Fang Pharmaceutical Co.,Ltd.

Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases

AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa

Advances in Targeting IL-1 Family Cytokines for Inflammatory Disease Treatment